Buy & Sell Public Storage (PSA) – Public Storage Price Today
Aura AI Summary
Key Stats
- $56.41BMarket Cap
- Real EstateSector
- -6.31%3M Drawdown
- $70.66BEnterprise Value
- 3.73%Dividend Yield
- 126 daysTypical Hold Time
Public Storage (PSA) is currently valued at a market capitalization of $56.41B, with an enterprise value of $70.66B. Over the past 52 weeks, Public Storage has traded between a low of $258.44 and a high of $325.94, highlighting its annual price range. Over the past three months, Public Storage has recorded a drawdown of -6.31%, reflecting recent price volatility. Public Storage offers a dividend yield of 3.73%, with the most recent dividend of $3.00 paid on 15 Jun 26. On average, investors hold Public Storage for approximately 126 days, indicating typical investor behavior on the platform.
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Most Recent News
Man Group discloses 1.57% stake in Senior Plc via derivatives as of June 23, 2026
Man Group PLC filed a Form 8.3 disclosure revealing it holds a 1.57% interest in Senior Plc, primarily through cash-settled derivatives, totaling 6,613,314 securities as of June 23, 2026. This disclosure is part of regulatory requirements under the T...

Bunzl Canada’s Cleaning & Hygiene division earns top Diamond status from Ontario Education Collaborative Marketplace.
Bunzl Canada's Cleaning & Hygiene division has achieved the Diamond status, the highest recognition from the Ontario Education Collaborative Marketplace (OECM) supplier program for 2025. This honor highlights Bunzl's consistent excellence in service,...

Biotech M&A heats up with Legend Biotech as top takeover target due to strong revenue and strategic fit.
Biotech mergers and acquisitions are gaining momentum as Big Pharma seeks to offset upcoming patent losses. Among potential targets, Legend Biotech stands out for its revenue-generating CAR-T therapy Carvykti, co-developed with Johnson & Johnson, sho...
